The primary therapeutic use of Beacita is to provide supportive assistance in the management of conditions related to excess body mass and help with maintaining long-term weight goals. The medication is used in conjunction with an individualized low-calorie, low-fat diet and exercise program to help patients lose weight.

Managing Weight and Associated Systemic Imbalance

This medication plays a role in managing conditions characterized by symptoms related to excessive body mass, specifically for adults classified as overweight (BMI 28 kg/m^2) who have associated health concerns, or those with obesity (BMI 30 kg/m^2). The primary therapeutic benefit contributes to supporting the patient's goal of weight reduction and contributes to maintaining a sense of stability.

The medicine is considered relevant for easing symptoms related to systemic imbalance often seen in high-BMI patients, such as symptoms linked to cholesterol fluctuations and assisting with the management of symptoms associated with blood sugar levels in those with Type 2 diabetes or impaired glucose tolerance. The key indications involve helping with excessive body mass, assisting with metabolic risk factor management, and supporting weight maintenance during the post-loss phase.

Quick Fact: Relief for Weight-Related Metabolic Stress The primary use is to support adults with a high BMI in managing symptoms related to systemic imbalance associated with weight and its common co-existing conditions, such as high cholesterol.

Regulatory References

1. NIH MedlinePlus Drug Information on Orlistat

Beacita (Orlistat) is an anti-obesity agent whose use is defined by specific population criteria in official regulatory documents. Eligibility is primarily based on Body Mass Index (BMI):

Classification	Eligibility Criteria (Regulatory Wording)
Allowed (Adults)	BMI 30 , kg/m^2 (obesity) or BMI 27 , kg/m^2 with associated health risk factors (e.g., hypertension, diabetes).
Allowed (Adolescents)	Approved for use in patients aged 12 years and older (prescription strength).

---

Populations For Whom Use is Contraindicated

Official labeling strictly contraindicates the medicine in patients with the following conditions or physiological states, meaning it must not be used:

• Chronic malabsorption syndrome.
• Cholestasis (obstructed bile flow from the liver).
• Pregnancy and Breastfeeding.
• Known hypersensitivity to Orlistat or any component of the product.
• Concurrent treatment with Ciclosporin (immunosuppressant) or Warfarin (anticoagulant), per some regulatory definitions.

---

Restricted and Age-Based Eligibility

Use is not established in children under 12 years of age and is not recommended for the 60 mg strength in children below 18 years of age. Patients with chronic kidney disease should use Beacita with caution due to the documented potential for hyperoxaluria and oxalate nephropathy. Data on the effect in elderly patients has been limited.

The interaction profile for Beacita is structured around the mechanism of reduced intestinal fat absorption, which affects the systemic exposure of several co-administered lipophilic substances. No drug-drug combinations are officially listed as contraindicated, but interactions may lead to loss of therapeutic control for certain critical medicines.

Exposure-Altering and Pharmacodynamic Interactions

Interacting Substance/Category	Official Interaction Statement
Fat-Soluble Vitamins (A, D, E, K)	Reduced absorption is documented, requiring supplementary administration.
Warfarin (Vitamin K Antagonists)	Potential for enhanced anticoagulant effect (prolonged INR) due to impaired Vitamin K absorption.
Cyclosporine & Amiodarone	Reduced systemic exposure (decreased blood levels) is observed for both immunosuppressant and antiarrhythmic agents.
Antiretroviral & Antiepileptic Drugs	Reduction in absorption may lead to decreased plasma concentration, posing a risk for loss of virological or seizure control.

Regulatory Restrictions and Timing Rules

To mitigate the risk of reduced exposure, administration timing rules are formally established. Levothyroxine (thyroid hormone) must be administered at least four hours apart from Beacita. Cyclosporine administration must be separated by at least three hours. Daily multivitamin supplements containing fat-soluble vitamins should be taken at least two hours before or two hours after. Regulatory documents also specify that the diet must be restricted to no more than 30% of total calories from fat. The product is formally contraindicated in patients with chronic malabsorption syndrome or cholestasis.

How Beacita Works: Mechanism of Action

Beacita's mechanism is defined by the peripheral covalent inhibition of digestive lipases. The active ingredient, Orlistat, acts specifically on gastric and pancreatic lipases within the lumen of the gastrointestinal tract. Orlistat forms a stable, covalent bond with the active-site serine residue of these enzymes, locking them into an inert state.

This molecular action results in the blockade of dietary triglyceride hydrolysis, which is the primary pathway effect. By preventing the breakdown of large fat molecules into absorbable free fatty acids, the drug ensures these triglycerides remain intact and non-utilizable by the body. The mechanistic cascade leads directly to a measurable physiological change: reduced net caloric absorption.

Since approximately one-third of ingested fat is excreted rather than metabolized, a consistent, localized negative energy balance is established, which drives the necessary physiological shift in energy balance. This mechanism is entirely dependent on the presence of dietary fat (the substrate) in the meal, defining a constraint on its efficacy and establishing a plateau of maximal fat absorption blockage.

How to Use Beacita: Administration Guidelines

Beacita (Orlistat 120 mg) is administered according to specific principles which synchronize the medicine's use with dietary intake.

---

Administration Protocol

Feature	Description
Route of Administration	The medicine is formulated for oral use, taken as a hard capsule
Standard Dosing	The standard adult dose is one 120 mg capsule per administration. The maximum permitted daily intake is 360 mg (three capsules).
Frequency and Timing	Dosing is set at three times daily (TID), taken with each main meal that contains fat.

---

Contextual and Procedural Requirements

Proper use of Beacita is directly linked to dietary control and timing:

• Meal Synchronization: The capsule must be taken immediately before, during, or up to one hour after a main meal containing fat. If a meal is missed or contains no fat, the corresponding dose must be omitted.
• Dietary Requirement: The treatment is only used alongside a nutritionally balanced, reduced-calorie diet in which approximately 30% of total calories come from fat.
• Supplementation: Due to potential reduced absorption of fat-soluble vitamins (A, D, E, K), a multivitamin supplement should be taken at least two hours before or after the Beacita dose, or at bedtime.

---

Course Duration and Continuation

Specific criteria apply to the continuation of therapy:

• Treatment should be discontinued after 12 weeks if the patient has not achieved a weight loss of at least 5% of their initial body weight.
• The use of the medicine should not exceed a duration of 2 years, as safety and efficacy data beyond this period are not available.

Research evidence / Overview of Studies for Beacita (Orlistat)

---

Evidence for Weight Loss in Adults with Obesity (BMI ge 30 kg/m^2)

Research on the active ingredient in Beacita, Orlistat, has primarily used Randomized Controlled Trials (RCTs) and systematic reviews to explore the evaluation of the compound in adults classified as having obesity. These studies monitored participants taking the active ingredient alongside a reduced-calorie diet, comparing their progress to groups taking a placebo pill and following the same diet. The studies were used in research exploring how symptoms change over time and typically monitored participants for periods ranging from six months to two years.

Studies monitored outcomes related to physical discomfort by tracking measurements like the overall percentage change in body weight and the Body Mass Index (BMI). Data show patterns related to measurements observed in the studies, and trials also tracked the proportion of individuals who achieved certain weight loss thresholds, such as a 5% or 10% reduction from their starting weight.

---

Evidence for Overweight Adults with Health Risk Factors (BMI ge 28 kg/m^2)

Research has explored the compound's evaluation in specific subgroups of patients who were overweight (BMI ge 28 kg/m^2) but had other conditions, such as high cholesterol or markers for blood sugar concerns. These studies focused on conditions associated with acute or disruptive episodes linked to excess body mass.

In addition to tracking weight loss, research examined outcomes related to systemic or functional imbalance, such as tracking measurements of blood lipids (total and LDL cholesterol) and blood sugar markers (fasting plasma glucose and HbA1c). Data show patterns related to shifts in these metabolic markers during the study period.

---

Long-Term Evidence and Durability of Results

Research has explored the long-term patterns related to measured outcomes by conducting controlled trials that involve an initial weight loss phase followed by an extended maintenance phase. The longest follow-up durations available for the active ingredient extend up to four years of continuous or intermittent observation.

These maintenance studies monitored the key outcome of weight regain in participants who had successfully lost weight initially. Findings describe patterns observed in the studies where participants receiving the active ingredient were associated with a pattern of difference in weight regain measurements compared to those in the control group over the maintenance phase.

---

Key Limitations and Uncertainties in the Research

The research base for Beacita has focused on specific areas and includes several key limitations. Follow-up durations were limited in many of the initial trials, which means that the long-term effects are not fully established beyond the four-year maintenance phase.

A major concern cited in scientific literature is the consistently high rate of patient discontinuation observed in studies, which makes it challenging to draw broad conclusions across the entire patient population. The results apply only to the populations studied and reflect the specific conditions under which the research was conducted.

Key Studies & References

1. Orlistat for the treatment of obesity in adults (Technology appraisal guidance TA22)
2. Orlistat - StatPearls - NCBI Bookshelf

Common questions about Beacita (FAQ)

---

Q: Is Beacita safe to use during pregnancy?

According to official product information, there are currently no available human data to evaluate the risks of using Beacita during pregnancy. Animal studies revealed findings such as reduced gestation length and effects on developing offspring at exposures at or above the maximum recommended human dose. Therefore, the relevance of these animal findings to human risk is not clear.

---

Q: Should I take Beacita with food or on an empty stomach?

Official prescribing information indicates that Beacita may be taken with or without food. This condition for administration is specified in the regulatory documents.

How to Store and Dispose of Beacita?

Regulatory documentation defines specific storage and disposal instructions to maintain the stability of Beacita (orlistat) and ensure environmental compliance.

---

Mandatory Storage Conditions

Requirement Type	Official Condition
Temperature	Store at a temperature not exceeding 25 C; keep from freezing.
Protection	Must be stored in the original package to protect from light and moisture.
Safety	Keep the medicinal product out of the sight and reach of children.

---

Disposal Requirements

Unused or expired Beacita must be handled as pharmaceutical waste. Official instructions state that the medicine must be disposed of in accordance with local requirements and must not be thrown away via wastewater or standard household waste.